Reaping the benefits of renal protective lipid autacoids

Drug Discovery Today: Disease Mechanisms

Volumn 4, Issue 1, 2007, Pages 3-10

  Gronert, Karsten ^a   Hassan, Iram R ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AUTACOID; DOCOSAHEXAENOIC ACID; ICOSANOID; LIPID; LIPOXIN; LIPOXIN A; LIPOXIN A DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PROTECTIN D1; RESOLVIN D1;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; DISEASE EXACERBATION; GLOMERULONEPHRITIS; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; NONHUMAN; PATHOPHYSIOLOGY; RENAL PROTECTION; REVIEW;

EID: 47049096786     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2007.06.002     Document Type: Review

References (46)

1. Gilroy D.W., et al. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. 3 (2004) 401-416
2. Kumar V., et al. Robbins and Cotran Pathological Basis of Disease (2004), W.B. Saunders Company
3. Serhan C.N., et al. Resolution of inflammation: state of the art, definitions and terms. FASEB. J. 21 (2007) 325-332
4. Bonventre J.V., and Zuk A. Ischemic acute renal failure: an inflammatory disease?. Kidney Int. 66 (2004) 480-485
5. Donadio J.V., and Grande J.P. IgA nephropathy. N. Engl. J. Med. 347 (2002) 738-748
6. Singbartl K., and Ley K. Leukocyte recruitment and acute renal failure. J. Mol. Med. 82 (2004) 91-101
7. Serhan C.N., and Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6 (2005) 1191-1197
8. Imig J.D. Eicosanoids and renal vascular function in diseases. Clin. Sci. (Lond.) 111 (2006) 21-34
9. McMahon B., and Godson C. Lipoxins: endogenous regulators of inflammation. Am. J. Physiol. Renal Physiol. 286 (2004) F189-F201
10. Chiang N., et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58 (2006) 463-487
11. Serhan C.N. Resolution phases of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25 (2006) 101-137
12. Kieran N.E., et al. Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney Int. 65 (2004) 1145-1154
13. Parkinson J.F. Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflamm. Allergy Drug Targets 5 (2006) 91-106
14. Munger K.A., et al. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13375-13380
15. Mayadas T.N., et al. Acute passive anti-glomerular basement membrane nephritis in P-selectin-deficient mice. Kidney Int. 49 (1996) 1342-1349
16. In: De Caterina R., et al. (Ed). n - 3 Fatty acids and Vascular Disease (1993), Springer-Verlag
17. Investigators G.-P. Dietary supplementation with n - 3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354 (1999) 447-455
18. Simopoulos A.P., et al. Workshop on the essentiality of an recommended dietary intakes for omega-6 and omega-3 fatty acids. J. Am. Coll. Nutr. 18 (1999) 487-489
19. Kromann N., and Green A. Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Medica Scandinavica 208 (1980) 401-406
20. Arterburn L.M., et al. Distribution, interconversion, and dose response of n - 3 fatty acids in humans. Am. J. Clin. Nutr. 83 6 Suppl. (2006) 1467S-1476S
21. Schaefer E.J., et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham heart study. Arch. Neurol. 63 (2006) 1545-1550
22. Ferrucci L., et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J. Clin. Endocrinol. Metab. 91 (2006) 439-446
23. Erkkila A.T., et al. Higher plasma docosahexaenoic acid is associated with reduced progression of coronary atherosclerosis in women with CAD. J. Lipid Res. 47 (2006) 2814-2819
24. Mori T.A. Omega-3 fatty acids and hypertension in humans. Clin. Exp. Pharmacol. Physiol. 33 (2006) 842-846
25. Donadio J.V., and Grande J.P. The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin Nephrol. 24 (2004) 225-243
26. Kielar M.L., et al. Docosahexaenoic acid ameliorates murine ischemic acute renal failure and prevents increases in mRNA abundance for both TNF-alpha and inducible nitric oxide synthase. J. Am. Soc. Nephrol. 14 (2003) 389-396
27. Jia Q., et al. Docosahexaenoic acid and eicosapentaenoic acid, but not alpha-linolenic acid, suppress deoxynivalenol-induced experimental IgA nephropathy in mice. J. Nutr. 134 (2004) 1353-1361
28. Tatsioni A., et al. Effects of fish oil supplementation on kidney transplantation: a systematic review and meta-analysis of randomized, controlled trials. J. Am. Soc. Nephrol. 16 (2005) 2462-2470
29. Keeney D.S., et al. Differentiating keratinocytes express a novel cytochrome P450 enzyme, CYP2B19, having arachidonate monooxygenase activity. J. Biol. Chem. 273 (1998) 32071-32079
30. Bylund J., et al. Analysis of cytochrome P450 metabolites of arachidonic and linoleic acids by liquid chromatography-mass spectrometry with ion trap MS. Anal. Biochem. 265 (1998) 55-68
31. Barbosa-Sicard E., et al. Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem. Biophys. Res. Commun. 329 (2005) 1275-1281
32. Lauterbach B., et al. Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activators. Hypertension 39 2 Pt 2 (2002) 609-613
33. Schwarz D., et al. Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns. Biochem. Biophys Res. Commun. 336 (2005) 779-783
34. Choudhary D., et al. Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab. Dispos. 32 (2004) 840-847
35. Titos E., et al. Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A(4). Am. J. Physiol. 277 5 Pt 1 (1999) C870-C877
36. Chiang N., et al. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 15178-15183
37. Bazan N.G. Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci. 29 (2006) 263-271
38. Kuhn H., and O'Donnell V.B. Inflammation and immune regulation by 12/15-lipoxygenases. Prog. Lipid. Res. 45 (2006) 334-356
39. Sraer J., et al. Metabolism of arachidonic acid via the lipoxygenase pathway in human and murine glomeruli. J. Biol. Chem. 258 (1983) 4325-4330
40. Reinhold S.W., et al. Gene expression of 5-, 12-, and 15-lipoxygenases and leukotriene receptors along the rat nephron. Am. J. Physiol. Renal Physiol. 290 (2006) F864-F872
41. Hassan I.R., and Gronert K. 15-Lipoxygenase and docosahexaenoic acid derived lipid mediators ameliorate inflammation and augment heme oxygenase-1 expression in acute renal failure. Prostagland. Other Lipid Mediat. 79 (2006) 158
42. Duffield J.S., et al. Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 177 (2006) 5902-5911
43. Abraham N.G., and Kappas A. Heme oxygenase and the cardiovascular-renal system. Free Radic. Biol. Med. 39 (2005) 1-25
44. Ryter S.W., et al. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol. Rev. 86 (2006) 583-650
45. Nascimento-Silva V., et al. Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am. J. Physiol. Cell Physiol. 289 (2005) C557-C563
46. Biteman, B. et al. Interdependence of lipoxin A4 and heme-oxygenase in counterregulating inflammation during corneal wound healing. FASEB J. (in press)